肝纤维化的代谢重编：聚焦于肝巨噬细胞与肝星状细胞的代谢网络
Metabolic Reprogramming in Liver Fibrosis: Focusing on the Metabolic Network of Hepatic Macrophages and Hepatic Stellate Cells
DOI: 10.12677/acm.2025.1551452, PDF,  被引量    科研立项经费支持
作者: 张沚汀, 韩 澳, 陈辉帆, 梁舒惟, 韦慧怡, 李 宇：广西中医药大学研究生院，广西 南宁；俞 渊*, 庞浇安：广西中医药大学第一附属医院肝胆外科，广西 南宁；黎舒琴：钦州市第一人民医院产科，广西 钦州
关键词: 肝纤维化；肝巨噬细胞；肝星状细胞；Liver Fibrosis； Hepatic Macrophages； Hepatic Stellate Cell
摘要: 肝纤维化是由慢性肝损伤引发的肝细胞外基质(Extracellular Matrix, ECM)异常沉积和结构紊乱过程，终末可发展为肝硬化(Liver Cirrhosis)和肝细胞癌(Hepatocellular Carcinoma, HCC)。近年研究表明，代谢重编通过重塑肝巨噬细胞(Kupffer细胞/MoMϕs)和肝星状细胞(HSCs)的代谢网络，驱动纤维化进程。本文系统探讨两种关键细胞的代谢特征、互作机制及靶向干预策略，为开发新型抗纤维化疗法提供理论依据。
Abstract: Liver fibrosis is a pathological process characterized by abnormal deposition and structural disorganization of the extracellular matrix (ECM) triggered by chronic liver injury, which can ultimately progress to liver cirrhosis and hepatocellular carcinoma (HCC). Recent studies have demonstrated that metabolic reprogramming drives the fibrogenic process by reshaping the metabolic networks of hepatic macrophages (Kupffer cells/MoMϕs) and hepatic stellate cells (HSCs). This article systematically explores the metabolic characteristics, interaction mechanisms, and targeted intervention strategies of these two key cell types, providing a theoretical foundation for the development of novel anti-fibrotic therapies.
文章引用：张沚汀, 俞渊, 庞浇安, 韩澳, 陈辉帆, 梁舒惟, 韦慧怡, 李宇, 黎舒琴. 肝纤维化的代谢重编：聚焦于肝巨噬细胞与肝星状细胞的代谢网络[J]. 临床医学进展, 2025, 15(5): 931-940. https://doi.org/10.12677/acm.2025.1551452

参考文献

[1] Roehlen, N., Crouchet, E. and Baumert, T.F. (2020) Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells, 9, Article 875. [Google Scholar] [CrossRef] [PubMed]
[2] Devarbhavi, H., Asrani, S.K., Arab, J.P., Nartey, Y.A., Pose, E. and Kamath, P.S. (2023) Global Burden of Liver Disease: 2023 Update. Journal of Hepatology, 79, 516-537. [Google Scholar] [CrossRef] [PubMed]
[3] Delgado, M.E., Cárdenas, B.I., Farran, N. and Fernandez, M. (2021) Metabolic Reprogramming of Liver Fibrosis. Cells, 10, Article 3604. [Google Scholar] [CrossRef] [PubMed]
[4] Li, J., Zhai, X., Sun, X., Cao, S., Yuan, Q. and Wang, J. (2022) Metabolic Reprogramming of Pulmonary Fibrosis. Frontiers in Pharmacology, 13, Article 1031890. [Google Scholar] [CrossRef] [PubMed]
[5] Zhu, X., Jiang, L., Long, M., Wei, X., Hou, Y. and Du, Y. (2021) Metabolic Reprogramming and Renal Fibrosis. Frontiers in Medicine, 8, Article 746920. [Google Scholar] [CrossRef] [PubMed]
[6] Park-Min, K. (2019) Metabolic Reprogramming in Osteoclasts. Seminars in Immunopathology, 41, 565-572. [Google Scholar] [CrossRef] [PubMed]
[7] Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., et al. (2019) Crosstalk between Adipose Tissue Insulin Resistance and Liver Macrophages in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 71, 1012-1021. [Google Scholar] [CrossRef] [PubMed]
[8] 江海燕, 钟芳芳, 张俊平. 肝巨噬细胞与肝纤维化研究进展[J]. 药学实践与服务, 2024, 42(4): 135-140.
[9] 王慜婷, 许丰, 张谢. 肝星状细胞调控肝纤维化的相关机制研究进展[J]. 中国现代医生, 2024, 62(31): 94-97.
[10] Zhao, J., Zhang, S., Liu, Y., He, X., Qu, M., Xu, G., et al. (2020) Single-Cell RNA Sequencing Reveals the Heterogeneity of Liver-Resident Immune Cells in Human. Cell Discovery, 6, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[11] Tacke, F. and Zimmermann, H.W. (2014) Macrophage Heterogeneity in Liver Injury and Fibrosis. Journal of Hepatology, 60, 1090-1096. [Google Scholar] [CrossRef] [PubMed]
[12] Ma, X., Qiu, J., Zou, S., Tan, L. and Miao, T. (2024) The Role of Macrophages in Liver Fibrosis: Composition, Heterogeneity, and Therapeutic Strategies. Frontiers in Immunology, 15, Article 1494250. [Google Scholar] [CrossRef] [PubMed]
[13] Wen, Y., Lambrecht, J., Ju, C. and Tacke, F. (2020) Hepatic Macrophages in Liver Homeostasis and Diseases-Diversity, Plasticity and Therapeutic Opportunities. Cellular & Molecular Immunology, 18, 45-56. [Google Scholar] [CrossRef] [PubMed]
[14] Heymann, F. and Tacke, F. (2016) Immunology in the Liver—From Homeostasis to Disease. Nature Reviews Gastroenterology & Hepatology, 13, 88-110. [Google Scholar] [CrossRef] [PubMed]
[15] Hu, C., Xuan, Y., Zhang, X., Liu, Y., Yang, S. and Yang, K. (2022) Immune Cell Metabolism and Metabolic Reprogramming. Molecular Biology Reports, 49, 9783-9795. [Google Scholar] [CrossRef] [PubMed]
[16] Park, S., Lee, J., Seo, H., Hwang, S.S., Lee, C. and Lee, G.R. (2025) Modulation of Immune Responses by Metabolic Reprogramming: The Key Role of Immunometabolism. Immune Network, 25, e15. [Google Scholar] [CrossRef] [PubMed]
[17] Murray, P.J. (2017) Macrophage Polarization. Annual Review of Physiology, 79, 541-566. [Google Scholar] [CrossRef] [PubMed]
[18] Ma, P., Gao, C., Yi, J., Zhao, J., Liang, S., Zhao, Y., et al. (2017) Cytotherapy with M1-Polarized Macrophages Ameliorates Liver Fibrosis by Modulating Immune Microenvironment in Mice. Journal of Hepatology, 67, 770-779. [Google Scholar] [CrossRef] [PubMed]
[19] Marrocco, A. and Ortiz, L.A. (2022) Role of Metabolic Reprogramming in Pro-Inflammatory Cytokine Secretion from LPS or Silica-Activated Macrophages. Frontiers in Immunology, 13, Article 936167. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, Y., Xu, R., Gu, H., Zhang, E., Qu, J., Cao, W., et al. (2021) Metabolic Reprogramming in Macrophage Responses. Biomarker Research, 9, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[21] Xu, F., Guo, M., Huang, W., Feng, L., Zhu, J., Luo, K., et al. (2020) Annexin A5 Regulates Hepatic Macrophage Polarization via Directly Targeting PKM2 and Ameliorates Nash. Redox Biology, 36, Article ID: 101634. [Google Scholar] [CrossRef] [PubMed]
[22] Dong, G., Mao, Q., Xia, W., Xu, Y., Wang, J., Xu, L., et al. (2016) PKM2 and Cancer: The Function of PKM2 Beyond Glycolysis. Oncology Letters, 11, 1980-1986. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, P., Li, H., Gong, J., Geng, Y., Jiang, M., Xu, H., et al. (2022) Chitooligosaccharides Alleviate Hepatic Fibrosis by Regulating the Polarization of M1 and M2 Macrophages. Food & Function, 13, 753-768. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, P., Lou, L., Sharma, B., Li, M., Xie, C., Yang, F., et al. (2024) Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications. Current Medicinal Chemistry, 31, 2955-2973. [Google Scholar] [CrossRef] [PubMed]
[25] Li, Q., Cao, L., Tian, Y., Zhang, P., Ding, C., Lu, W., et al. (2018) Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming. Molecular & Cellular Proteomics, 17, 1531-1545. [Google Scholar] [CrossRef] [PubMed]
[26] 姚树坤, 刘婧, 周天惠. 代谢相关脂肪性肝病的发病机制与中医病机[J]. 临床肝胆病杂志, 2024, 40(10): 1954-1958.
[27] Luo, W., Ai, L., Wang, B., Wang, L., Gan, Y., Liu, C., et al. (2020) Eccentric Exercise and Dietary Restriction Inhibits M1 Macrophage Polarization Activated by High-Fat Diet-Induced Obesity. Life Sciences, 243, Article ID: 117246. [Google Scholar] [CrossRef] [PubMed]
[28] Lv, Q., Gao, R., Peng, C., Yi, J., Liu, L., Yang, S., et al. (2017) Bisphenol a Promotes Hepatic Lipid Deposition Involving Kupffer Cells M1 Polarization in Male Mice. Journal of Endocrinology, 234, 143-154. [Google Scholar] [CrossRef] [PubMed]
[29] 汤莉, 吴伶莉. 原发性肝癌患者肠道菌群变化与内毒素和炎性因子水平的关系[J]. 中国微生态学杂志, 2021, 33(10): 1162-1165.
[30] Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., et al. (2018) Inhibition of Monoacylglycerol Lipase, an Anti-Inflammatory and Antifibrogenic Strategy in the Liver. Gut, 68, 522-532. [Google Scholar] [CrossRef] [PubMed]
[31] Shao, T., Chen, Z., Rong, J., Belov, V., Chen, J., Jeyarajan, A., et al. (2022) [18F]MAGL-4-11 Positron Emission Tomography Molecular Imaging of Monoacylglycerol Lipase Changes in Preclinical Liver Fibrosis Models. Acta Pharmaceutica Sinica B, 12, 308-315. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, F., Zhang, S., Vuckovic, I., Jeon, R., Lerman, A., Folmes, C.D., et al. (2018) Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation. Cell Metabolism, 28, 463-475.e4. [Google Scholar] [CrossRef] [PubMed]
[33] Stifel, U., Caratti, G. and Tuckermann, J. (2022) Novel Insights into the Regulation of Cellular Catabolic Metabolism in Macrophages through Nuclear Receptors. FEBS Letters, 596, 2617-2629. [Google Scholar] [CrossRef] [PubMed]
[34] Ma, S., Murakami, K., Tanaka, K., Hashimoto, M., Tanaka, M., Kitagori, K., et al. (2022) Fatostatin Ameliorates Inflammation without Affecting Cell Viability. FEBS Open Bio, 12, 594-604. [Google Scholar] [CrossRef] [PubMed]
[35] Brovkovych, V., Izhar, Y., Danes, J.M., Dubrovskyi, O., Sakallioglu, I.T., Morrow, L.M., et al. (2018) Fatostatin Induces Pro-and Anti-Apoptotic Lipid Accumulation in Breast Cancer. Oncogenesis, 7, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[36] Zhao, Y., Wang, L., Liu, M., Du, A., Qiu, M., Shu, H., et al. (2023) ROS Inhibition Increases KDM6A-Mediated NOX2 Transcription and Promotes Macrophages Oxidative Stress and M1 Polarization. Cell Stress and Chaperones, 28, 375-384. [Google Scholar] [CrossRef] [PubMed]
[37] Huang, C., Gan, D., Luo, F., Wan, S., Chen, J., Wang, A., et al. (2019) Interaction Mechanisms between the NOX4/ROS and RhoA/ROCK1 Signaling Pathways as New Anti-Fibrosis Targets of Ursolic Acid in Hepatic Stellate Cells. Frontiers in Pharmacology, 10, Article 431. [Google Scholar] [CrossRef] [PubMed]
[38] Yang, G., Ni, J., Li, Y., Zha, M., Tu, Y. and Li, K. (2021) Acceptor Engineering for Optimized ROS Generation Facilitates Reprogramming Macrophages to M1 Phenotype in Photodynamic Immunotherapy. Angewandte Chemie International Edition, 60, 5386-5393. [Google Scholar] [CrossRef] [PubMed]
[39] Zhang, N., Guo, F. and Song, Y. (2023) HOXC8/TGF-β1 Positive Feedback Loop Promotes Liver Fibrosis and Hepatic Stellate Cell Activation via Activating Smad2/smad3 Signaling. Biochemical and Biophysical Research Communications, 662, 39-46. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, J., Liu, Y., Chen, H., Yuan, Q., Wang, J., Niu, M., et al. (2022) MyD88 in Hepatic Stellate Cells Enhances Liver Fibrosis via Promoting Macrophage M1 Polarization. Cell Death & Disease, 13, Article No. 411. [Google Scholar] [CrossRef] [PubMed]
[41] 王慜婷, 许丰, 张谢. 肝星状细胞调控肝纤维化的相关机制研究进展[J]. 中国现代医生, 2024, 62(31): 94-97.
[42] 阿比丹∙拜合提亚尔, 郭津生. 肝纤维化发生时活化肝星状细胞的代谢改变[J]. 中国细胞生物学学报, 2021, 43(10): 2054-2060.
[43] Pan, M., Li, H. and Shi, X. (2024) A New Target for Hepatic Fibrosis Prevention and Treatment: The Warburg Effect. Frontiers in Bioscience-Landmark, 29, Article 321. [Google Scholar] [CrossRef] [PubMed]
[44] 廖昭辉 ,谢正元. 肝纤维化发病的分子机制及其相关治疗靶点的研究进展[J]. 吉林大学学报(医学版), 2024, 50(5): 1450-1456.
[45] Zhou, M., Cheng, M., Huang, T., Hu, R., Zou, G., Li, H., et al. (2021) Transforming Growth Factor β-1 Upregulates Glucose Transporter 1 and Glycolysis through Canonical and Noncanonical Pathways in Hepatic Stellate Cells. World Journal of Gastroenterology, 27, 6908-6926. [Google Scholar] [CrossRef] [PubMed]
[46] Wan, L., Xia, T., Du, Y., Liu, J., Xie, Y., Zhang, Y., et al. (2019) Exosomes from Activated Hepatic Stellate Cells Contain GLUT1 and PKM2: A Role for Exosomes in Metabolic Switch of Liver Nonparenchymal Cells. The FASEB Journal, 33, 8530-8542. [Google Scholar] [CrossRef] [PubMed]
[47] Czuba, L.C. and Isoherranen, N. (2024) LX-2 Stellate Cells Are a Model System for Investigating the Regulation of Hepatic Vitamin a Metabolism and Respond to Tumor Necrosis Factor Α and Interleukin 1β. Drug Metabolism and Disposition, 52, 442-454. [Google Scholar] [CrossRef] [PubMed]
[48] Zheng, D., Jiang, Y., Qu, C., Yuan, H., Hu, K., He, L., et al. (2020) Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and Liver Fibrosis. The American Journal of Pathology, 190, 2267-2281. [Google Scholar] [CrossRef] [PubMed]
[49] Yoneda, A., Sakai-Sawada, K., Niitsu, Y. and Tamura, Y. (2016) Vitamin A and Insulin Are Required for the Maintenance of Hepatic Stellate Cell Quiescence. Experimental Cell Research, 341, 8-17. [Google Scholar] [CrossRef] [PubMed]
[50] Chen, M., Liu, J., Yang, W. and Ling, W. (2017) Lipopolysaccharide Mediates Hepatic Stellate Cell Activation by Regulating Autophagy and Retinoic Acid Signaling. Autophagy, 13, 1813-1827. [Google Scholar] [CrossRef] [PubMed]
[51] Alkhouri, N., Dixon, L.J. and Feldstein, A.E. (2009) Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal. Expert Review of Gastroenterology & Hepatology, 3, 445-451. [Google Scholar] [CrossRef] [PubMed]
[52] Lee, E., Lee, J., Kim, D., Lee, Y., Jo, Y., Dao, T., et al. (2024) Loss of SREBP-1c Ameliorates Iron-Induced Liver Fibrosis by Decreasing Lipocalin-2. Experimental & Molecular Medicine, 56, 1001-1012. [Google Scholar] [CrossRef] [PubMed]
[53] Du, K., Chitneni, S.K., Suzuki, A., Wang, Y., Henao, R., Hyun, J., et al. (2020) Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. Cellular and Molecular Gastroenterology and Hepatology, 10, 1-21. [Google Scholar] [CrossRef] [PubMed]
[54] Zhang, M., Serna-Salas, S., Damba, T., Borghesan, M., Demaria, M. and Moshage, H. (2021) Hepatic Stellate Cell Senescence in Liver Fibrosis: Characteristics, Mechanisms and Perspectives. Mechanisms of Ageing and Development, 199, Article ID: 111572. [Google Scholar] [CrossRef] [PubMed]
[55] de Oliveira da Silva, B., Ramos, L.F. and Moraes, K.C.M. (2017) Molecular Interplays in Hepatic Stellate Cells: Apoptosis, Senescence, and Phenotype Reversion as Cellular Connections That Modulate Liver Fibrosis. Cell Biology International, 41, 946-959. [Google Scholar] [CrossRef] [PubMed]
[56] Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B.S., Schwabl, P., Trauner, M., et al. (2021) Nuclear Receptors in Liver Fibrosis. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1867, Article ID: 166235. [Google Scholar] [CrossRef] [PubMed]
[57] Nelson, V.L., Nguyen, H.C.B., Garcìa-Cañaveras, J.C., Briggs, E.R., Ho, W.Y., DiSpirito, J.R., et al. (2018) PPARγ Is a Nexus Controlling Alternative Activation of Macrophages via Glutamine Metabolism. Genes & Development, 32, 1035-1044. [Google Scholar] [CrossRef] [PubMed]
[58] Bennett, R.G., Simpson, R.L. and Hamel, F.G. (2017) Serelaxin Increases the Antifibrotic Action of Rosiglitazone in a Model of Hepatic Fibrosis. World Journal of Gastroenterology, 23, 3999-4006. [Google Scholar] [CrossRef] [PubMed]
[59] Preethi, S., Arthiga, K., Patil, A.B., Spandana, A. and Jain, V. (2022) Review on NAD(P)H Dehydrogenase Quinone 1 (NQO1) Pathway. Molecular Biology Reports, 49, 8907-8924. [Google Scholar] [CrossRef] [PubMed]
[60] Xue, J., Xiao, T., Wei, S., Sun, J., Zou, Z., Shi, M., et al. (2021) miR‐21‐Regulated M2 Polarization of Macrophage Is Involved in Arsenicosis‐induced Hepatic Fibrosis through the Activation of Hepatic Stellate Cells. Journal of Cellular Physiology, 236, 6025-6041. [Google Scholar] [CrossRef] [PubMed]
[61] Hellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., et al. (2003) Peroxisome Proliferator-Activated Receptor-β Signaling Contributes to Enhanced Proliferation of Hepatic Stellate Cells. Gastroenterology, 124, 184-201. [Google Scholar] [CrossRef] [PubMed]
[62] Francque, S., Szabo, G., Abdelmalek, M.F., Byrne, C.D., Cusi, K., Dufour, J., et al. (2020) Nonalcoholic Steatohepatitis: The Role of Peroxisome Proliferator-Activated Receptors. Nature Reviews Gastroenterology & Hepatology, 18, 24-39. [Google Scholar] [CrossRef] [PubMed]
[63] Endo-Umeda, K., Kim, E., Thomas, D.G., Liu, W., Dou, H., Yalcinkaya, M., et al. (2022) Myeloid LXR (Liver X Receptor) Deficiency Induces Inflammatory Gene Expression in Foamy Macrophages and Accelerates Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, 719-731. [Google Scholar] [CrossRef] [PubMed]
[64] Endo-Umeda, K., Nakashima, H., Umeda, N., Seki, S. and Makishima, M. (2018) Dysregulation of Kupffer Cells/Macrophages and Natural Killer T Cells in Steatohepatitis in LXRα Knockout Male Mice. Endocrinology, 159, 1419-1432. [Google Scholar] [CrossRef] [PubMed]
[65] Zhong, L., Ning, B., Du, X., et al. (2019) Liver X receptor; Controls Hepatic Stellate Cell Activation via Hedgehog Signaling. bioRxiv.
[66] Jaroonwitchawan, T., Arimochi, H., Sasaki, Y., Ishifune, C., Kondo, H., Otsuka, K., et al. (2023) Stimulation of the Farnesoid X Receptor Promotes M2 Macrophage Polarization. Frontiers in Immunology, 14, Article 1065790. [Google Scholar] [CrossRef] [PubMed]
[67] Shi, T., Malik, A., Yang vom Hofe, A., Matuschek, L., Mullen, M., Lages, C.S., et al. (2022) Farnesoid X Receptor Antagonizes Macrophage-Dependent Licensing of Effector T Lymphocytes and Progression of Sclerosing Cholangitis. Science Translational Medicine, 14, eabi4354. [Google Scholar] [CrossRef] [PubMed]
[68] Manka, P., Coombes, J.D., Sydor, S., Swiderska‐Syn, M.K., Best, J., Gauthier, K., et al. (2023) Thyroid Hormone Receptor α Modulates Fibrogenesis in Hepatic Stellate Cells. Liver International, 44, 125-138. [Google Scholar] [CrossRef] [PubMed]

为你推荐